Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Comment by Craiger02on Nov 04, 2021 9:45pm
99 Views
Post# 34090094

RE:The termination of the ATM Program Canaccord

RE:The termination of the ATM Program Canaccord

this could be a very good thing or it could be nothing. Very possible that news coming shortly. 


SamV21 wrote:  today the termination of its previously announced "at-the-market" equity offering program (the "ATM Program") with Canaccord Genuity Corp. as sole agent.

The termination of the ATM Program is effective as of November 11, 2021. Tetra will not be using the ATM Program. The ATM Program was established on May 28, 2021, allowing the Company to issue and sell up to $10 million aggregate amount of common shares of the Company to the public from time to time, at the Company's discretion. As of the date of this announcement, Tetra had not sold any of its common shares under the ATM Program



<< Previous
Bullboard Posts
Next >>